1910 Genetics vs Ochre Bio

<p>1910 Genetics is an AI-driven software platform that transforms drug discovery by combining massive multimodal data, advanced AI models, and high-throughput laboratory automation. It targets scientists, researchers, and biotech companies aiming to innovate therapeutics effectively. By leveraging its proprietary ITO™ platform and PEGASUS™ AI model, you can speed up the development of breakthrough small and large molecule drugs, including macrocyclic peptides.</p> <p>With 1910 Genetics, you get a cohesive environment that supports collaboration, molecular design, and data integration tailored for AI-enabled discovery. You can also engage in co-engineering services to build customized drug discovery modules using interactive tools such as dashboards and chatbots. This platform is designed to push innovation boundaries in biotech, helping you get drugs to market faster with more precision and efficiency.</p>

<p>Ochre Bio is a cutting-edge platform that combines AI with large-scale human liver data to accelerate drug discovery specifically for chronic liver diseases. It enables you to explore causal disease mechanisms, validate targets in human tissue, and develop RNA therapies in-house, significantly reducing R&amp;D timelines. The platform targets the pharmaceutical industry and research organizations aiming to find effective treatments beyond liver transplants.</p> <p>With investments in proprietary datasets and integrated gene atlases, Ochre Bio supports discovery, validation, and clinical development pipelines. You benefit from access to mechanistic insights, RNA therapeutic development, and partnerships with leading companies like GSK. This platform aims to revolutionize liver disease treatment by making drug development faster and more precise.</p>